Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pear Therapeutics Inc.

www.peartherapeutics.com

Latest From Pear Therapeutics Inc.

NESTcc Test Case List Includes Apple Watch, Pelvic Mesh

The National Evaluation System for health Technology Coordinating Center announced 12 new test cases that use real-world evidence to examine medical device industry priorities. The list includes an Apple Watch study, as well as an FDA proposal on the use of pelvic mesh to treat urinary incontinence.

Health Technology Assessment Review Pathway

Cipla Backs Start-Up As It Builds Digital Health Strategy

Cipla has picked up a minority holding in the Indian digital therapeutics firm Wellthy, and the duo will combine forces to improve patient outcomes in specific chronic therapies.
Commercial Strategy

Finance Watch: 5AM, Longevity Close Funds, New Incubators Launch To Support Early-Stage Companies

News of 5AM's two latest venture funds follows the launch of Longevity Vision Fund as well as LA BioMed's and RUNLABS’ announcements that they will open new incubators in 2019. Also, Passage Bio launches with $115.5m, but the largest recent VC deal was HaiHe's $146.6m financing.

Financing StartUps and SMEs

Venture Funding Deals: Vedanta Raises More Cash To Advance Microbiome Candidates

Cancer drug-developer Black Diamond emerges from stealth mode with Series A and closes Series B in the same month, while aging-focused Juvenescence closes its initial tranche and looks complete Series B by the end of the quarter. 

Deals Financing
See All

Company Information

  • Industry
  • Digital Health
  • Medical Devices
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Inflammation
  • Neurology, Nervous System
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Pear Therapeutics Inc.
  • Senior Management
  • Guiffre Christopher, CFO & CEO
    Alex Waldron, Chief Commercial Officer
    Ian McFarland, General Mgr. & CTO
    Yuri Maricich , MD, Acting CMO & Head, Clinical Dev.
  • Contact Info
  • Pear Therapeutics Inc.
    745 Atlantic Ave.
    Boston, MA 02111
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register